Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ITM Isotope Technologies Munich SE

< Previous 1 2 Next >
ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Appoints Dr. Mark Harfensteller as Member of its Executive Board
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Reports on Participation at 3rd ICPO Forum for Theranostics in Precision Oncology and Announces Support for ICPO Academy for Theranostics
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Host Theranostics Symposium on Clinical Need and Supply at SNMMI Annual Meeting on Sunday, June 25, 2023
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Appoints Roger Estafanos as U.S. General Manager and Expands Presence with Opening of U.S. Headquarters in Princeton, New Jersey
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present Phase III COMPOSE Poster and Host Satellite Symposium on Radiotheranostics in NET cancer at ENETS Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present at the 41st Annual J.P. Morgan Healthcare Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM: Isotope Production System Begins Commercial Production of Cancer-Fighting Lutetium-177
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Multiplies Production Capacity for its n.c.a. Lutetium-177
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Host Scientific Precision Oncology Symposium in Parallel to the ASCO Annual Meeting on Friday, June 03, 2022
From ITM Isotope Technologies Munich SE
Via Business Wire
ITM Announces Successful Completion of Patient Recruitment for its Phase III Trial, COMPETE, with Lead Radiotherapeutic ITM-11 (n.c.a. 177Lu-edotreotide)
From ITM Isotope Technologies Munich SE
Via Business Wire
ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer
From ITM Isotope Technologies Munich SE
Via Business Wire
ITM Receives Equity Investment of EUR 25 Million from Strategic Partner Grand Pharma
From ITM Isotope Technologies Munich SE
Via Business Wire
ITM Announces First Patient Treated in Second Phase III Trial, COMPOSE, with ITM-11 (n.c.a. 177Lu-edotreotide) for Treatment of Neuroendocrine Tumors
From ITM Isotope Technologies Munich SE
Via Business Wire
ITM: Installation of New Isotope Production System at Bruce Power to Produce Medical Isotopes for Cancer Therapy Completed
From ITM Isotope Technologies Munich SE
Via Business Wire
ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme
From ITM Isotope Technologies Munich SE
Via Business Wire
ITM Isotope Technologies Munich to Present at the 40th Annual J.P. Morgan Healthcare Conference
From ITM Isotope Technologies Munich SE
Via Business Wire
ITM and Grand Pharma Enter into a Commercialization Agreement for Targeted Radiopharmaceuticals in the Greater China Area
From ITM Isotope Technologies Munich SE
Via Business Wire
ITM and ANSTO Announce Extension of Licensing Agreement for the Production and Supply of the Medical Radioisotope n.c.a. Lutetium-177
From ITM Isotope Technologies Munich SE
Via Business Wire
ITM and Navigo Proteins Announce Research Collaboration to Develop FAP-targeting Radionuclide Therapy to Address Solid Tumors
From ITM Isotope Technologies Munich SE
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.